神经肿瘤学会成立30周年:科学进展与创新回顾
神经肿瘤学会(SNO)于2025年迎来成立30周年,本文回顾了该领域三十年来的科学进步与未来方向。SNO通过年会、儿科神经肿瘤和脑转移瘤专科会议及四本期刊,推动了全球临床、转化和基础研究。科学里程碑包括分子分型整合入中枢神经系统肿瘤分类、神经影像进展、靶向治疗及脑转移瘤管理演变。
要点
- SNO成立30年推动神经肿瘤学教育、指导和全球协作。
- 分子分型已整合入中枢神经系统肿瘤分类。
- 脑转移瘤管理从全脑放疗演变为多模式策略。
核心结论
- SNO成立30年来催化了神经肿瘤学的科学创新、教育、指导和全球协作,改善了原发性和转移性脑肿瘤患者的诊疗。
研究设计与样本
- 本文为神经肿瘤学会成立30周年的回顾性文章,总结该领域科学进展与未来方向。
主要发现
- SNO通过年会、儿科神经肿瘤和脑转移瘤专科会议及包括Neuro-Oncology在内的四本期刊建立知识传播平台。
- 科学里程碑包括分子分型整合入中枢神经系统肿瘤分类、神经影像用于诊断和治疗监测的进展。
- 部分胶质瘤患者靶向治疗取得进展,脑转移瘤管理从全脑放疗演变为结合靶向和免疫治疗的多模式策略。
- 儿科神经肿瘤学在组织分子诊断、风险分层和新型靶向药物方面取得进展,并更重视生存者管理。
- 肿瘤微环境和新型免疫治疗方法的见解为未来发现和转化提供方向。
临床怎么用
- 临床可关注分子分型在中枢神经系统肿瘤分类中的应用。
- 脑转移瘤治疗可考虑靶向和免疫治疗参与的多模式策略。
- 儿科神经肿瘤诊疗可结合组织分子诊断和 refined 风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Society for Neuro-Oncology (SNO) marks its 30th anniversary in 2025, providing an opportunity to reflect on scientific advances and future directions in the field. Over 3 decades, SNO has catalyzed scientific innovation, education, mentorship, and global collaboration, advancing the care of patients with primary and metastatic brain tumors. Through its annual meeting and subspecialty conferences in pediatric neuro-oncology and brain metastases, as well as its journals, including Neuro-Oncology, Neuro-Oncology Practice, Neuro-Oncology Advances, and the recently launched Neuro-Oncology Pediatrics, SNO has established leading platforms for disseminating knowledge, sharing best practices, and shaping clinical, translational, and basic research worldwide. Scientific milestones during this period include the integration of molecular profiling into central nervous system tumor classification, advances in neuroimaging for diagnosis and treatment monitoring, targeted therapies for selected glioma patients, and the evolution of brain metastases management from whole-brain radiotherapy to multimodal strategies that incorporate targeted and immune-based therapies. Pediatric neuro-oncology has similarly advanced with the use of histomolecular diagnostics, refined risk stratification, and the development of novel targeted agents, alongside an increased emphasis on survivorship. Looking forward, emerging insights into the tumor microenvironment and novel immunotherapeutic approaches offer promising directions for future discovery and translation.
引用
- de la Fuente MI, Brastianos PK, Gampel B, et al. Reflecting on scientific growth and innovation as the Society for Neuro-Oncology turns 30. Neuro Oncol. 2026. PMID: 41191923. doi:10.1093/neuonc/noaf255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。